Reference
1. Schwabe S. Oxcarbazepine: clinical development program.Epilepsia . 1994;35 Suppl 5:S51-3. doi:10.1111/j.1528-1157.1994.tb05968.x
2. Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs . 2001;15(2):137-63. doi:10.2165/00023210-200115020-00005
3. Schachter SC. Oxcarbazepine: current status and clinical applications. Expert Opin Investig Drugs . Jul 1999;8(7):1103-12. doi:10.1517/13543784.8.7.1103
4. Maiti R, Mishra BR, Sanyal S, Mohapatra D, Parida S, Mishra A. Effect of carbamazepine and oxcarbazepine on serum neuron-specific enolase in focal seizures: A randomized controlled trial. Epilepsy Res . Dec 2017;138:5-10. doi:10.1016/j.eplepsyres.2017.10.003
5. Schütz H, Feldmann KF, Faigle JW, Kriemler HP, Winkler T. The metabolism of 14C-oxcarbazepine in man. Xenobiotica . Aug 1986;16(8):769-78. doi:10.3109/00498258609043567
6. May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet . 2003;42(12):1023-42. doi:10.2165/00003088-200342120-00002
7. Di Girolamo G, Opezzo JA, Schere D, Gonzalez CD, Moncalvo JJ. Parent drug and/or metabolite? Which of them is most appropriate to establish bioequivalence of two oral oxcarbazepine formulations in healthy volunteers? Expert Opin Pharmacother . Jul 2007;8(10):1415-23. doi:10.1517/14656566.8.10.1415
8. Lu Y, Fang Y, Wu X, Ma C, Wang Y, Xu L. Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy. Eur J Clin Pharmacol . Mar 2017;73(3):307-315. doi:10.1007/s00228-016-2157-3
9. van Heiningen PN, Eve MD, Oosterhuis B, et al. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine.Clin Pharmacol Ther . Oct 1991;50(4):410-9. doi:10.1038/clpt.1991.158
10. Patsalos PN, Elyas AA, Zakrzewska JM. Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia. Eur J Clin Pharmacol . 1990;39(4):413-5. doi:10.1007/bf00315422
11. Flesch G. Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Investig . 2004;24(4):185-203. doi:10.2165/00044011-200424040-00001
12. Rouan MC, Lecaillon JB, Godbillon J, et al. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites.Eur J Clin Pharmacol . 1994;47(2):161-7. doi:10.1007/bf00194967
13. Sachdeo R, Beydoun A, Schachter S, et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology . Sep 11 2001;57(5):864-71. doi:10.1212/wnl.57.5.864
14. Bring P, Ensom MH. Does oxcarbazepine warrant therapeutic drug monitoring? A critical review. Clin Pharmacokinet . 2008;47(12):767-78. doi:10.2165/0003088-200847120-00002
15. Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res . Oct 1972;5(5):411-59. doi:10.1016/0010-4809(72)90051-1
16. Sasaki T, Tabuchi H, Higuchi S, Ieiri I. Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting. Pharmacogenomics . Aug 2009;10(8):1257-66. doi:10.2217/pgs.09.65
17. Kanji S, Hayes M, Ling A, et al. Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement. Clin Pharmacokinet . Jul 2015;54(7):783-95. doi:10.1007/s40262-015-0236-8
18. Jamsen KM, McLeay SC, Barras MA, Green B. Reporting a population pharmacokinetic-pharmacodynamic study: a journal’s perspective.Clin Pharmacokinet . Feb 2014;53(2):111-22. doi:10.1007/s40262-013-0114-1
19. Burns DR, Elswick RK, Jr. Equivalence testing with dental clinical trials. J Dent Res . Jun 2001;80(6):1513-7. doi:10.1177/00220345010800060701
20. Ahmad A, Garnett WR. Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations. Curr Med Res Opin . Sep 2005;21(9):1363-8. doi:10.1185/030079905x59120
21. Ling J, Qian LX, Ding JJ, Jiao Z. [Effects of multiple-trough sampling design and algorithm on the estimation of population and individual pharmacokinetic parameters]. Yao Xue Xue Bao . May 2014;49(5):686-94.
22. Liu M, Ma CL, Jiao Z, Gao YC, Liu YX, Wu XY. Population pharmacokinetics of oxcarbazepine in Chinese epilepsy patients. Article.Yaoxue Xuebao . 2018;53(8):1318-1323. doi:10.16438/J.0513-4870.2018-0187
23. Sallas WM, Milosavljev S, D’Souza J, Hossain M. Pharmacokinetic drug interactions in children taking oxcarbazepine. Clin Pharmacol Ther . Aug 2003;74(2):138-49. doi:10.1016/s0009-9236(03)00124-3
24. Sugiyama I, Bouillon T, Yamaguchi M, Suzuki H, Hirota T, Fink M. Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities. Drug Metab Pharmacokinet . Apr 2015;30(2):160-7. doi:10.1016/j.dmpk.2014.12.002
25. Northam RS, Hernandez AW, Litzinger MJ, et al. Oxcarbazepine in infants and young children with partial seizures. Pediatr Neurol . Nov 2005;33(5):337-44. doi:10.1016/j.pediatrneurol.2005.05.011
26. Park KJ, Kim JR, Joo EY, et al. Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy. Clin Neuropharmacol . Jan-Feb 2012;35(1):40-4. doi:10.1097/WNF.0b013e31824150a5
27. Peng J, Zhang HN, Liu ZS, Xu H, Wang Y. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy.Int J Clin Pharmacol Ther . Aug 2014;52(8):684-92. doi:10.5414/cp202078
28. Wang Y, Zhang HN, Niu CH, et al. Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. Acta Pharmacol Sin . Oct 2014;35(10):1342-50. doi:10.1038/aps.2014.76
29. Lin WW, Wang CL, Jiao Z, et al. Glomerular Filtration Rate Is a Major Predictor of Clearance of Oxcarbazepine Active Metabolite in Adult Chinese Epileptic Patients: A Population Pharmacokinetic Analysis.Ther Drug Monit . Oct 2019;41(5):665-673. doi:10.1097/ftd.0000000000000644
30. Lin WW, Li XW, Jiao Z, et al. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens. Eur J Clin Pharmacol . Mar 2019;75(3):381-392. doi:10.1007/s00228-018-2600-8
31. Chen CY, Zhou Y, Cui YM, Yang T, Zhao X, Wu Y. Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy. J Clin Pharm Ther . Apr 2019;44(2):300-311. doi:10.1111/jcpt.12792
32. Rodrigues C, Chiron C, Rey E, et al. Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.Br J Clin Pharmacol . Dec 2017;83(12):2695-2708. doi:10.1111/bcp.13392
33. Yu Y, Zhang Q, Xu W, Lv C, Hao G. Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy. Eur J Drug Metab Pharmacokinet . Aug 2016;41(4):345-51. doi:10.1007/s13318-015-0266-5
34. Antunes NJ, van Dijkman SC, Lanchote VL, et al. Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. Eur J Pharm Sci . Nov 15 2017;109s:S116-s123. doi:10.1016/j.ejps.2017.05.034
35. Wegner I, Edelbroek P, de Haan GJ, Lindhout D, Sander JW. Drug monitoring of lamotrigine and oxcarbazepine combination during pregnancy. Epilepsia . Dec 2010;51(12):2500-2. doi:10.1111/j.1528-1167.2010.02771.x
36. Comets E, Brendel K, Mentré F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed . May 2008;90(2):154-66. doi:10.1016/j.cmpb.2007.12.002
37. Ahn JE, Birnbaum AK, Brundage RC. Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses. J Pharmacokinet Pharmacodyn . Dec 2005;32(5-6):703-18. doi:10.1007/s10928-005-0083-6
38. Perucca E. Pharmacokinetic variability of new antiepileptic drugs at different ages. Ther Drug Monit . Dec 2005;27(6):714-7. doi:10.1097/01.ftd.0000179847.37965.4e
39. Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet . 2006;45(4):351-63. doi:10.2165/00003088-200645040-00002
40. Choonara IA, McKay P, Hain R, Rane A. Morphine metabolism in children. Br J Clin Pharmacol . Nov 1989;28(5):599-604. doi:10.1111/j.1365-2125.1989.tb03548.x
41. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet . Jun 1999;36(6):439-52. doi:10.2165/00003088-199936060-00005
42. Piña-Garza JE, Espinoza R, Nordli D, et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures.Neurology . Nov 8 2005;65(9):1370-5. doi:10.1212/01.wnl.0000186800.18456.72
43. McKee PJ, Blacklaw J, Forrest G, et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients.Br J Clin Pharmacol . Jan 1994;37(1):27-32. doi:10.1111/j.1365-2125.1994.tb04234.x
44. French JA, Baroldi P, Brittain ST, Johnson JK. Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial. Acta Neurol Scand . Mar 2014;129(3):143-53. doi:10.1111/ane.12207
45. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs–best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia . Jul 2008;49(7):1239-76. doi:10.1111/j.1528-1167.2008.01561.x